{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:25:41Z","timestamp":1761060341555,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11845-017-1625-9","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T06:09:46Z","timestamp":1493791786000},"page":"189-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent\u2019s University Hospital over a 6-month period"],"prefix":"10.1007","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-0988","authenticated-orcid":false,"given":"J.","family":"Lambe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Noone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lonergan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tubridy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"key":"1625_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1568016043356192","volume":"2","author":"F Barbey","year":"2004","unstructured":"Barbey F, Hayoz D, Widmer U et al (2004) Efficacy of enzyme replacement therapy in Fabry disease. Curr Med Chem- Cardiovascular and hematological agents 2:277\u2013286. doi:\n10.2174\/1568016043356192","journal-title":"Curr Med Chem- Cardiovascular and hematological agents"},{"issue":"S447","key":"1625_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/08035320510028076","volume":"94","author":"A Mehta","year":"2005","unstructured":"Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr 94(S447):24\u201327. doi:\n10.1080\/08035320510028076","journal-title":"Acta Paediatr"},{"key":"1625_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/hrt.2005.063818","volume":"93","author":"A Linhart","year":"2007","unstructured":"Linhart A, Elliot PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93:528\u2013535. doi:\n10.1136\/hrt.2005.063818","journal-title":"Heart"},{"key":"1625_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M et al (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry registry. Stroke 40:788\u2013794. doi:\n10.1161\/STROKEAHA.108.526293","journal-title":"Stroke"},{"key":"1625_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani R, Wolf M, West ML et al (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249\u2013255. doi:\n10.1046\/j.1523-1755.2002.00097.x","journal-title":"Kidney Int"},{"key":"1625_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1538-7836.2008.02903.x","volume":"6","author":"F Guercini","year":"2008","unstructured":"Guercini F, Acciarresi M, Agnelli G et al (2008) Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 6:549\u2013554. doi:\n10.1111\/j.1538-7836.2008.02903.x","journal-title":"J Thromb Haemost"},{"issue":"9499","key":"1625_CR7","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","volume":"366","author":"A Rolfs","year":"2005","unstructured":"Rolfs A, Bottcher T, Zschiesche M et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366(9499):1794\u20131796. doi:\n10.1016\/S0140-6736(05)67635-0","journal-title":"Lancet"},{"issue":"2","key":"1625_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis 30(2):184\u2013192. doi:\n10.1007\/s10545-007-0521-2","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"1625_CR9","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","volume":"64","author":"G Altarescu","year":"2005","unstructured":"Altarescu G, Moore DF, Schiffmann R (2005) Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 64(12):2148\u20132150. doi:\n10.1212\/01.WNL.0000166000.24321.4F","journal-title":"Neurology"},{"issue":"1","key":"1625_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3978\/j.issn.2224-4336.2015.12.02","volume":"5","author":"C Ellaway","year":"2016","unstructured":"Ellaway C (2016) Paediatric Fabry disease. Transl Pediatr 5(1):37\u201342. doi:\n10.3978\/j.issn.2224-4336.2015.12.02","journal-title":"Transl Pediatr"},{"key":"1625_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ymgme.2013.03.008","volume":"109","author":"MG Bouwman","year":"2013","unstructured":"Bouwman MG, de Ru MH, Linthorst GE et al (2013) Fabry patients\u2019 experiences with the timing of diagnosis relevant for the discussion on newborn screening. Mol Genet Metab 109:201\u2013207. doi:\n10.1016\/j.ymgme.2013.03.008","journal-title":"Mol Genet Metab"},{"key":"1625_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386. doi:\n10.7326\/0003-4819-146-2-200701160-00148","journal-title":"Ann Intern Med"},{"key":"1625_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","volume":"28","author":"B Najafian","year":"2013","unstructured":"Najafian B, Mauer M, Hopkin RJ et al (2013) Renal complications of Fabry disease in children. Pediatr Nephrol 28:679\u2013687. doi:\n10.1007\/s00467-012-2222-9","journal-title":"Pediatr Nephrol"},{"key":"1625_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137\u2013148. doi:\n10.1681\/ASN.2012030316","journal-title":"J Am Soc Nephrol"},{"key":"1625_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","volume":"83","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Feldt-Rasmussen U, Rasmussen AK et al (2013) Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet 83:432\u2013438. doi:\n10.1111\/j.1399-0004.2012.01947.x","journal-title":"Clin Genet"},{"key":"1625_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DDDT.S11985","volume":"5","author":"U Ramaswami","year":"2011","unstructured":"Ramaswami U (2011) Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther 5:155\u2013173. doi:\n10.2147\/DDDT.S11985","journal-title":"Drug Des Devel Ther"},{"key":"1625_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","volume":"81","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Parini R, Pintos-Morell G et al (2012) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 81:485\u2013490. doi:\n10.1111\/j.1399-0004.2011.01671.x","journal-title":"Clin Genet"},{"key":"1625_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE et al (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254. doi:\n10.1001\/jama.281.3.249","journal-title":"JAMA"},{"key":"1625_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","volume":"105","author":"B Sachdev","year":"2002","unstructured":"Sachdev B, Takenaka T, Teraguchi H et al (2002) Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407\u20131411. doi:\n10.1161\/01.CIR.0000012626.81324.38","journal-title":"Circulation"},{"key":"1625_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 333:288\u2013293. doi:\n10.1056\/NEJM199508033330504","journal-title":"N Engl J Med"},{"issue":"3","key":"1625_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ageing\/afr141","volume":"41","author":"S Smith","year":"2012","unstructured":"Smith S et al (2012) The cost of stroke and transient ischaemic attack in Ireland: a prevalence-based estimate. Age Ageing 41(3):332\u2013338. doi:\n10.1093\/ageing\/afr141","journal-title":"Age Ageing"},{"issue":"7","key":"1625_CR22","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1161\/STROKEAHA.115.012281","volume":"47","author":"A Bersano","year":"2016","unstructured":"Bersano A et al (2016) Clinical pregenetic screening for stroke monogenic diseases: results from Lombardia GENS registry. Stroke 47(7):1702\u20131709. doi:\n10.1161\/STROKEAHA.115.012281","journal-title":"Stroke"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-017-1625-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T18:32:04Z","timestamp":1517596324000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-017-1625-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1007\/s11845-017-1625-9","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2017,5,3]]}}}